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S100P protein in human breast cancer cells is associated with reduced patient survival and, 
in a model system of metastasis, it confers a metastatic phenotype upon benign mammary 
tumour cells. S100P protein possesses a C-terminal lysine residue. Using a multiwell in 
vitro assay, S100P is now shown for the first time to exhibit a strong, C-terminal-lysine-
dependent activation of tissue plasminogen activator (tPA), but not of urokinase-catalysed 
plasminogen activation.  The presence of 10 μM calcium ions stimulates tPA activation of 
plasminogen 2-fold in an S100P-dependent manner. S100P physically interacts with both 
plasminogen and tPA in vitro, but not with urokinase.  Cells constitutively expressing 
S100P exhibit detectable S100P protein on the cell surface and S100P-containing cells 
show enhanced activation of plasminogen compared with S100P-negative control cells. 
S100P shows C-terminal-lysine-dependent enhancement of cell invasion.  An S100P 
antibody, when added to the culture medium, reduced the rate of invasion of wild-type 
S100P-expressing cells, but not of cells expressing mutant S100P proteins lacking the C-
terminal lysine, suggesting that S100P functions outside the cell. The protease inhibitors, 
aprotinin or α−2-antiplasmin, reduced the invasion of S100P-expressing cells, but not of 
S100P-negative control cells, nor cells expressing S100P protein lacking the C-terminal 
lysine. It is proposed that activation of tissue plasminogen activator via the C-terminal 
lysine of S100P contributes to the enhancement of cell invasion by S100P and thus 
potentially to its metastasis-promoting activity. 
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Introduction 
Certain S100 proteins, S100A4 and S100P, when present individually in patients’ 
cancers are associated with reduced patient survival [1-8], an association that is a likely 
consequence of the ability of these proteins to confer upon cells a metastatic phenotype.   
For S100A4, its elevated expression in two independent transgenic mouse models 
induces metastasis of oncogene-induced, non-metastatic tumours in the mammary gland 
[9, 10]. In an in vivo model system of breast cancer metastasis, expression of either 
S100A4 [11] or S100P [7] in a non-metastatic benign rat mammary tumour cell line 
results in the induction of a metastatic phenotype. It is now evident that intracellular 
S100A4 can enhance multiple properties contributing to the induction of a metastatic 
phenotype, including the activation of cell migration [12, 13], arising from a specific 
interaction with non-muscle myosin isoform A [14], alteration in apoptotic capability, 
by interaction with the tumour suppressor protein, p53 [15] and enhanced invasion 
through the stimulation of expression of metalloproteinases [16].  Furthermore, 
extracellular S100A4, as high molecular weight associations, has been reported to act on 
endothelial cells to induce angiogenesis [17] and to activate plasminogen activators in 
vitro by a mechanism similar to that of S100A10 [18].   
 
S100A10, a subunit of the annexin 2 tetramer, promotes plasminogen activation when 
its C-terminal lysines are displayed at the cell surface [19], particularly on endothelial 
cells [20].  The displayed C-terminal lysine residues interact with lysine-binding 
Kringle domains in plasminogen and tissue plasminogen activator proteins in the 
extracellular milieu [21]. In macrophages, this interaction leads to enhanced invasion 
[22]. 
 
The molecular mechanisms whereby S100P induces a metastatic phenotype are much 
less well understood than for S100A4. In common with other S100 proteins, the S100P 
monomer contains a high and a low affinity calcium binding site [23]. The low affinity 
calcium binding site can bind Mg2+ and the high affinity calcium binding site also binds 
Zn2+ [24], although interaction is unlikely at recently-determined free intracellular 
(cytoplasmic) and extracellular concentrations of zinc [25, 26] and magnesium [27] 
ions. Using analytical ultracentrifugation experiments, it has been shown that the 
oligomeric state of the S100P molecule varies according to the calcium concentration 
[24]. 
 
S100P has been reported to interact with the cell-membrane-actin-cross linking protein, 
Ezrin [28], and the cytoskeletal protein IQGAP1 [29], however, any consequences of 
such interaction in the context of cancer metastasis or even cell invasion are so far 
unknown. S100P interacts specifically with, and causes dissociation of, non-muscle 
myosin II isoforms A and C, with a consequential reduction in vinculin-containing focal 
adhesions, an increase in cell motility and reduced cell adhesion [30]. The likelihood is 
that, as with S100A4, S100P exerts its metastasis-inducing properties via a number of 
separate pathways, including cell invasion.  However, apart from an association of 
S100P with the RAGE receptor and epithelial mesenchymal transition [31], none of the 
present protein targets of S100P have been reported to have an S100P-associated role in 
the cellular invasion process.  Since S100P contains a C-terminal lysine, it is possible 
that one such pathway is the activation of plasminogen.  In this paper, we show for the 
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first time that S100P can activate plasminogen activators and that this activity 
contributes to the metastasis-associated biological property of cell invasion in S100P-
expressing cells with metastatic potential [7]. 
 
Materials and Methods 
 
Cell lines and pools  
The benign rat mammary tumour cell line, Rama 37 [32], was used in the present 
experiments because expression of S100P in these cells has been shown to confer a 
metastatic phenotype [7].  Rama 37 cells were transfected, as described previously [33] 
with empty PBK-CMV plasmid expression vector or PBK-CMV vector containing a 
cDNA encoding wild type human S100P protein, or a mutant S100P protein in which the 
C-terminal lysine has been replaced with alanine, designated K95A, or a mutant S100P 
protein lacking the C-terminal lysine, designated ΔK95. Cell clones and pools were 
isolated as described previously [33] and cultured in Dulbecco’s modified Eagle’s medium 
(DMEM) with 10% (v/v) foetal calf serum, as described previously [11] with 1 mg/mL 
G418 included for all transfected cells. These cloned and pooled cell lines exhibit similar 
levels of S100P as determined by Western blotting (Supplementary information 1).  In 
some experiments, an existing S100P inducible system, Rama 37-T25 was utilised [30], 
with cells cultured as above and wild type human S100P protein production being induced 
with 1 μg/mL doxycycline for 24 h.  
 
Transwell cell invasion assays were carried out using 8µm pore-size BioCoat Matrigel 
Invasion plates (BD Biosciences, MA).  The chambers were rehydrated for at least 2 h by 
adding warm, serum-free DMEM to the interior of the upper chambers and to the lower 
wells.  Following rehydration, the wells were filled with 750 µL of DMEM containing 5% 
(v/v) foetal calf serum.  The upper chambers were filled with 500 µL of the cell suspension 
containing 25,000 cells in DMEM with 1% (v/v) serum and were inserted into the wells.  
The plates were incubated for 22 h in a humidified tissue culture incubator at 37˚C with a 
10 % (v/v) CO2 atmosphere.  The non-invading cells on the upper surface were removed by 
gentle, but firm, scrubbing using a cotton-tipped swab.  The invading cells on the lower 
surface of the membrane were stained by Diff-Quik solution, the membrane was removed 
using a sharp scalpel blade and the cells were counted using a light microscope [34].   
 
Detection of S100P on the cell surface by enzyme-linked immunosorbent assay 
For analysis of extracellular and cell surface-bound S100P, quantification of the protein 
was carried out using an adapted enzyme-linked immunosorbent assay (ELISA) directly 
on living cells, as previously described [35]. Briefly 10,000 cells were seeded in 96-
well plates and grown for 48 h. To assess the presence of S100P or eukaryotic 
elongation factor 1A (eEF1A) as an intracellular marker in both intracellular and 
extracellular fractions, cells were either incubated in the presence of antibody for 1 h 
prior to fixing, or fixed prior to antibody addition, or fixed, permeabilised and incubated 
with antibody directed against either S100P (R&D Systems) or eEF1A (Merck 
Millipore). Fixation was carried out using 3.7% (w/v) paraformaldehyde in phosphate-
buffered saline (PBS) for 20 min at room temperature, whilst permeabilisation was 
achieved by incubating cells in 0.5% (v/v) Triton-X100 in PBS for 20 min at room 
temperature. Following the incubation with the primary antibody, wells were washed 
with blocking buffer (5% (w/v) dried skimmed milk in PBS, pH 7.4) prior to incubation 
with an appropriate horseradish-peroxidase-labelled secondary antibody for 2 h at room 
temperature. After subsequent washing, the reaction was developed using o-
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phenylenediamine dihydrochloride substrate (Sigma, UK) and absorbance read at 450 
nm using a multiwell plate reader.    
 
Production of recombinant wild type and mutant S100P proteins   
His-tagged wild type and mutant recombinant (r)S100P proteins were produced in BL21 
(DE3) E. coli cells (Thermo Fisher), as described previously [33]. rS100P-positive 
fractions eluted from a HisTrap column (GE Healthcare) were buffer-exchanged into 50 
mM Tris-HCl pH 8.0, 250 mM NaCl and the tag cleaved by addition of thrombin- agarose 
resin (Sigma) for 20 h at room temperature. Residual uncleaved protein and the cleaved 
His tag were removed by passing the supernatant from the cleavage reaction through a 
HisTrap column, and the flow-through, containing rS100P protein without the His tag, was 
then passed down a Superdex ® 75 gel filtration column (GE Healthcare) into 50 mM 
HEPES (pH 7.4), 250 mM NaCl (Supplementary information 2). Size Exclusion 
Chromatography-Multi-Angle Light Scattering (SEC-MALS) was carried out as described 
previously [36]. 
 
 
Plasminogen activation assays in vitro   
Assays were performed as described by Semov et al. [18].  rS100P protein, 100 nM 
Glu-plasminogen (Millipore) and 125 μM chromozyme PL (Roche) were pre-incubated 
for 60 min at room temperature in a reaction buffer consisting of 50 mM Tris-HCl (pH 
7.4) and 100 mM NaCl, with or without CaCl2. The reaction was initiated by the 
addition of tissue Plasminogen Activator (tPA) (Millipore) or urokinase-type 
Plasminogen Activator (uPA) (Millipore) as indicated in the figure legends and 
activation of plasminogen was measured by an increase in optical density at 405 nm for 
2 h, at 2-min intervals. 
 
For measurement of the activation of plasminogen activators by cultured cells, 2,000 
cells were seeded in each well of a Corning 24-flat-bottomed-well plate and allowed to 
attach for 24 h.  Attached cells were washed twice in PBS and incubated in 100 nM 
Glu-plasminogen and 125 μM chromozyme PL (Roche) in PBS.  Plasminogen 
activation was initiated by the addition of tPA in a final volume of 500 μL for 1 h.  The 
activation of plasminogen by tPA was measured by the increase in optical density at 405 
nm of samples withdrawn at 10-min intervals. 
 
Interaction between S100P, plasminogen and plasminogen activators   
Surface plasmon resonance (SPR) experiments were conducted in a Biacore X-100 
instrument (GE Healthcare). Proteins were immobilised on CM5 chips, using amine 
coupling chemistry, as described previously [37]. Experiments were carried out using a 
running buffer consisting of 10 mM HEPES (pH 7.4), 150 mM NaCl, added CaCl2 as 
specified in the Results section and 1 mg/mL carboxymethyl dextran (Sigma), at a flow 
rate of 30 µL/min at 25°C. Binding kinetics were studied using multi-cycle kinetic 
analysis, with surfaces regenerated using 1 mM EGTA between cycles. When used, 6-
aminocaproic acid (6-ACA) and EGTA were added to the analyte samples only, not to 
the running buffer. Binding constants were calculated using BiaEvaluation software 2.0 
(GE Healthcare). Association and dissociation of S100P with tPA occurred very rapidly, 
and thus Kd values for tPA interactions were determined at equilibrium. Glu-
plasminogen binding constants were assessed using standard kinetic analysis, as 
described previously [33]. 
 
  
  5 
Statistical analyses   
Stats Direct software version 3.0.181 was used for statistical analyses.  For single 
comparisons, Student’s t-test was used; for multiple comparisons, Analysis of Variance 
with Bonferroni post-hoc test was used. 
 
 
Results 
 
Plasminogen activator activation by S100P in vitro 
S100A10 and S100A4 have been reported to activate plasminogen activators by virtue 
of their C-terminal lysine residues [18, 38].  Since S100P also possesses a C-terminal 
lysine, we tested whether rS100P could regulate tPA-catalysed plasminogen activation 
using a multiwell assay. The production of active plasmin from Glu-plasminogen was 
monitored over time, by the appearance of a coloured product from a plasmin-specific 
substrate, as described in Materials and Methods, using a buffer containing 5 mM 
calcium ions. In the absence of tPA, no plasmin activity was detected either without 
(Figure 1, panels A, B or C) or with (not shown) 1 μM rS100P.  The addition of excess 
tPA led to the generation of plasmin activity from Glu-plasminogen after a short lag 
period (Figure 1). Increasing concentration of rS100P in the presence of tPA resulted in 
reduction in the lag period and increasing rates of plasminogen activation for up to at 
least 3.5 μM rS100P (Figure 1A).  Mutant rS100P proteins, ΔK95 (Figure 1B) or K95A 
(Figure 1C) were also tested in the multiwell plasminogen activation assay.  To aid 
comparison between the various recombinant proteins, the optical density readings were 
replotted against time2 and the resulting linear gradients over the first 30 min of 
incubation were determined. Removal, or replacement, of the C-terminal lysine 
markedly reduced the ability of rS100P to activate tPA (Figure 1D), demonstrating that 
S100P and its C-terminal lysine are required for activation of tPA.  
 
Effect of calcium ions on plasminogen activation   
Although S100P binds calcium [23] and has been reported to bind magnesium and zinc 
ions [24], S100P is unlikely to bind zinc or magnesium ions at their free intracellular or 
extracellular concentrations [25-27]. Thus, the dependence on only calcium concentration 
of tPA activation by S100P was determined (Figure 2A). There were statistically 
significant differences between calcium concentrations, as determined by one-way 
ANOVA (F(8,9) = 15.0, P = 0.0002).  Whilst plasminogen was activated in the presence of 
1 μM rS100P and excess tPA, the rate of activation was significantly increased by the 
presence of 10 μM Ca++ (95% CI = -0.00005 to -0.000018, P = 0.001, Bonferroni 
correction), but there was no further significant increase at higher calcium ion 
concentrations up to 10 mM (Figure 2A, 95% CI = -0.000025 to 0.000007, P >0.23, 
Bonferroni correction).  In the absence of rS100P and in the presence of excess (5 mM) 
calcium ions, the rate of plasminogen activation was not significantly different from that 
with no calcium (95% CI = -0.000007 to 0.000025, P = 0.25, Bonferroni correction), 
suggesting that the increase in plasminogen activator activity in the presence of calcium 
ions was due to an effect on the rS100P protein by calcium ions. In contrast, 1 μM bovine 
serum albumin (BSA), in the presence of calcium ions, did not significantly change the 
initial rate of plasminogen activation by tPA (Figure 2B) (95% CI = -0.000011 to 
0.000024, P = 0.32, Bonferroni correction), under conditions when there was a significant 
activation by 1 μM rS100P (95% CI = -0.000076 to -0.000041, P = 0.002, Bonferroni 
correction), showing that the activation observed with rS100P is not a general property of 
lysine-containing proteins (Figure 2B). Size Exclusion Chromatography-Multi Angle Light 
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Scattering experiments indicated that > 96% of wild type and mutant S100P proteins were 
in the dimeric form at calcium concentrations of both 50 and 500 μM (Supplementary 
information 3).   
 
Effect of concentration of rS100P and its mutants on tPA-dependent activation of 
plasminogen  
Increasing concentrations of rS100P up to 100 nM in the presence of 5 mM calcium ions 
resulted in a significantly increased initial rate of tPA-dependent plasminogen activation in 
vitro (one-way ANOVA (F(6,7) = 24.4, P = 0.0002). Based on the initial gradients of plots 
of optical density vs time2, this effect started to plateau at concentrations of rS100P above 
100 nM (Figure 2C). Significant detectable enhancement of the initial rate of plasminogen 
activation by excess tPA occurred between 50 and 100 nM (600 - 1200 ng/mL) rS100P (50 
nM, 95% CI -0.000031 to 0.000003, P = 0.09; 100 nM, 95% CI = -0.000055 to -0.000021, 
P = 0.0012, Bonferroni correction) (Figure 2C).    
 
There were significant differences between the ability of wild type and mutant S100P 
proteins to activate plasminogen activators (one-way ANOVA (F(4,10) = 194.6, P < 
0.0001). Initial rates of plasminogen activation with 1 μM K95A-mutant or ΔK95-mutant 
rS100P were significantly lower than with wild type rS100P (95% CI, K95A-mutant, 
0.000031 to 0.000039 and ΔK95-mutant, 0.000028 to 0.000036, both P < 0.0001, 
Bonferroni correction) (Figure 2D), but both still exhibited residual activation of tPA that 
was significantly higher than the no-S100P control (95% CI, -0.00001 to -0.000003, P = 
0.004 and 95% CI, -0.000013 to -0.000005, P = 0.0003, respectively, Bonferroni 
correction), whereas, in the same experiment, 1μM BSA was not significantly different 
from the no-protein control (95% CI, -0.000004 to 0.000004, P = 0.98, Bonferroni 
correction) (Figure 2D). The results show that the C-terminal lysine is largely required for 
the ability of S100P to enhance the activity of tPA.  This enhancement might be due to 
interaction of the C-terminal lysines with lysine-binding Kringle domains of tPA and/or 
plasminogen.  
 
Interaction between S100P, plasminogen and plasminogen activators in vitro 
The binding of S100P to human plasminogen and tPA was measured using SPR as 
described in Materials and Methods.  Wild type rS100P bound to immobilised human 
Glu-plasminogen (Figure 3A) with a Kd of 0.12 µM (Supplementary information 4), a 
value that shows a greater affinity between Glu-plasminogen and S100P than between 
Glu-plasminogen and free lysine residues (43 μM; [39]).   Wild type rS100P bound to 
tPA with a Kd of 1.9 µM (Figure 3B and Supplementary information 4).  In the presence 
of the lysine analogue, 6-ACA, binding of wild type rS100P to either Glu-plasminogen 
(Figure 3A) or to tPA (Figure 3B) was markedly reduced, displaying Kd values of 84.0 
μM and 74.6 μM, respectively, confirming the involvement of lysine residues in the 
interaction of S100P with both plasminogen and tPA.  
 
Calcium chelation with EGTA resulted in only an approximately 50 % decrease in 
binding of wild type rS100P to Glu-plasminogen (Figure 3A), but completely abolished 
binding to tPA (Figure 3B), suggesting that activation of S100P by calcium is essential 
for interaction with tPA, but not for interaction with Glu-plasminogen. In contrast, the 
loss of the C-terminal lysine virtually abolished the interaction of S100P with Glu-
plasminogen (Figure 3A), but only partially reduced the extent of interaction of S100P 
with tPA (Figure 3B).  
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Although 1 μM wild type rS100P enhanced tPA-dependent plasminogen activation in 
the multiwell assay, the same concentration of S100P had no effect on urokinase (uPA)-
dependent plasminogen activation in the multiwell plasminogen activation assays, in the 
range zero to 50 nM uPA.  Whilst the initial rate of plasminogen activation increased 
with increasing uPA, there was no significant change in activity by 1 μM wild type 
rS100P at uPA concentrations of 1, 5 and 50 nM (P = 0.216, 0.089, 0.5 and 0.273, 
respectively), with S100P just significantly reducing activity at 10 and 25 nM (both, P = 
0.05, Student’s t test) (Figure 3C). In SPR experiments, wild type rS100P bound very 
poorly to uPA (Fig. 3C) and the bound protein dissociated only slowly from the uPA 
surface, in the time-frame of the experiment. This poor uPA-rS100P interaction likely 
accounts for the lack of rS100P-enhanced activation of plasminogen by uPA, whilst the 
very slow dissociation of rS100P from uPA might account for the reduction of uPA-
induced plasminogen activation in the presence of rS100P, as the build up of ‘inactive’ 
rS100P-uPA complexes could inhibit further interaction with plasminogen. Thus, 
rS100P does not activate uPA, but acts specifically on tPA.  
 
Cells expressing non-mutant S100P exhibit enhanced tPA-dependent plasminogen 
activation   
Following the demonstration of plasminogen activation by S100P protein in vitro, 
experiments were conducted to find out whether cells expressing S100P exhibited 
enhanced plasminogen activation, compared to non-expressing cells. Plasminogen 
activation assays were carried out using cells growing in culture wells, as described in 
Materials and Methods. PBS was found to be a satisfactory replacement for the Tris 
buffer system used in the plasminogen activation assays in vitro (Supplementary 
information 5).  
 
In order to compare the results of multiple experiments, the initial rates of colour 
development for the various cell lines in each experiment were expressed as a fraction 
of the result with cells expressing wild type S100P.  Figure 4 shows the results of six 
separate experiments.  In each case, cells not expressing S100P, or cells expressing the 
ΔK95 or K95A mutant S100P proteins exhibited reduced ability to activate Glu-
plasminogen in the presence of added tPA, compared to cells expressing wild type 
S100P (Figures 4A, results summarised in Figure 4B).   As further confirmation of the 
link between the production of S100P and the enhancement of tPA-catalysed 
plasminogen activation in cultured cells, an existing S100P inducible system was 
employed [30].  Induction of S100P with doxycycline for 24 h [30] increased the ability 
of the cells to activate plasminogen in the presence of tPA by 21.3% (P = 0.029, 
Student’s t test; Figure 4C).   
 
Detection of S100P on the outside of S100P-expressing cells   
In order to understand the ability of S100P-expressing cells to activate extracellularly-
added tPA, a quantitative enzyme-linked immunosorbent assay (ELISA) was used to detect 
S100P directly on the surface of living cells by adding an S100P polyclonal antibody 
directly to the cell culture medium or after fixation or permeabilisation (one-way ANOVA, 
(F(5,12) = 10.9), P = 0.0004). S100P antibody binding was detected at a significant (95% 
CI, -0.15 to -0.04, P= 0.0027, Bonferroni correction), 5.4-fold greater level in living 
unfixed cells expressing S100P, than from the cell line transfected with empty expression 
vector (Figure 5A, antibody in medium). A significantly higher level of S100P was 
detected also when the cells were fixed with formaldehyde (95% CI, - 0.11 to -0.00062, P 
= 0.05, Bonferroni correction), which was not significantly different from the level found 
when antibody was added directly to the medium (95% CI, -0.088 to 0.022, P = 0.22, 
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Bonferroni correction). Upon permeabilisation, a significantly higher optical density was 
evident with S100P-expressing cells compared to antibody added to the medium (95% CI, 
0.0017 to 0.112, P = 0.04, Bonferroni correction), possibly due to some of the intracellular 
S100P becoming available to the antibody.  In order to check that the antibody added to the 
medium was not reacting with intracellular S100P as a result of cell leakiness, an antibody 
to the soluble intracellular protein, eEF1A [40] was tested (eEF1A, (F(5,12) = 211.6), P = 
<0.0001).  In the ELISA assay, there was virtually no detectable binding of the eEF1A 
antibody when it was added to the medium in either S100P-expressing or control cells 
(Figure 5B).  However, after permeabilisation, there was a significant 134-fold increase in 
detectable eEF1A antibody binding in both S100P negative control cells (95% CI, -0.94 to 
-0.74, P < 0.0001) and in S100P-expressing cells (95% CI = -1.21 to -1.02, P< 0.0001) 
(Figure 5B), suggesting that under the conditions of the ELISA assay, the unfixed cells are 
intact and not leaking intracellular proteins, thus part of the detected S100P is displayed to 
the outside of the cells.  
 
Cell invasion by cells expressing S100P or its mutants 
Cells expressing wild type S100P exhibited a significant 9.4-fold (Figure 6A; 95% CI, 
330.5 to 357.5, P = <0.0001, Bonferroni correction) or 8.7-fold (Figure 6B; 95% CI, -162.9 
to -99.7, P = <0.0001, Bonferroni correction) increase in invasion through Matrigel in 
independent transwell invasion assays, when compared to S100P-negative, vector-
transfected control cells.  Such an increase was evident in both a clone and a pool of 
S100P-expressing transfected cells when compared to vector transfected or parental, 
untransfected, Rama 37 cells (Supplementary information 6). 
 
In contrast, cells expressing the K95A or Δ95K C-terminal mutants of S100P protein 
exhibited levels of invasion that were highly significantly lower than with wild type S100P 
(K95A mutant: Figure 7A, 95% CI, 316.9 to 343.8, P <0.0001; Figure 7B, 95% CI, 83.1 to 
146.3, P <0.0001; Δ95K mutant: Figure 6A, 95% CI, 347.9 to 374.8, P <0.0001; Figure 
6B, 95% CI = 98.742469 to 161.924197, P <0.0001) and not significantly different or 
significantly less than S100P-negative, vector-transfected control cells in two independent 
experiments (K95A mutant: Figure 6A, 95%  CI, 0.18 to 27.15, P = 0.05; Figure 6B, 95% 
CI = -48.3 to 14.9, P = 0.29 and  Δ95K mutant: Figure 6Α, 95% CI = -30.8 to -3.9, P = 
0.014; Figure 6B, CI = -32.6 to 30.6, P = 0.95).  Thus, altering or deleting the C-terminal 
lysine of S100P, which we have shown to be important for interacting with tPA and 
plasminogen, reduces its ability to enhance invasion of the Rama 37 cells. 
 
The effect of 6-aminocaproic acid on S100P dependent cell invasion 
To confirm the possible role of S100P lysine residues in the observed changes in cell  
invasion, 10 mM 6-amino caproic acid had no significant effect on S100P-negative vector 
control cells (95% CI = -20.1 to 6.8, P = 0.32), but significantly reduced by 32% the 
number of S100P positive cells invading through Matrigel (Figure 6A, 95% CI = 110.5 to 
137.5, P <0.0001). However, the invasion was still significantly higher than for S100P 
negative control cells (95% CI = 199.9 to 226.8, P <0.0001).  Invasion was also still 
significantly higher than with cells expressing the C-terminal mutants of S100P (K95A, 
95% CI = 192.9 to 219.8, P <0.0001; ΔK95, 95% CI = 223.9 to 250.8, P <0.0001).  This 
result indicates that lysine residues contribute significantly to S100P induced invasion, but 
that the dramatic reductions in invasion seen with the C-terminal lysine mutant proteins is 
not entirely due to the absence of the C-terminal lysine.   
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The effect of S100P antibody added to the culture medium on S100P-dependent 
invasion 
 
In invasion assays, addition of the S100P antibody to the medium surrounding wild type 
S100P-expressing cells (Figure 6B) reduced their invasion by a highly significant 57% 
from that of untreated cells (95% CI, 52.4 to 115.6, P = <0.0001), whereas non-immune 
goat serum added to the S100P-expressing cells had no significant effect (Figure 6C; 
95% CI, -46.8 to 99.5, P = 0.43).  Cells expressing K95A or ΔK95 mutant S100P 
proteins, or expressing no S100P, showed no significant reduction in invasion upon 
treatment with the antibody (Figure 6B; K95A,95% CI, -47.3 to 15.9, P = 0.32; ΔK95, 
95% CI, -36.9 to 26.2, P= 0.73; vector control, 95% CI, -47.3 to 15.9, P = 0.32). As it is 
unlikely that the S100P antibody can pass into the cells, these results suggest that the 
stimulatory effect of S100P on invasion depends upon wild-type S100P being accessible 
from outside the cell and this is not evident with cells expressing S100P protein lacking 
the C-terminal lysine, S100P negative cells nor with non-immune serum. 
 
The effect of protease inhibitors on the rate of S100P-dependent invasion  
In order to find out whether the generation of plasmin was associated with the lysine-
associated invasive behaviour of the cells, the effects of protease inhibitors on cell invasion 
were tested. Aprotinin, an inhibitor of serine proteases, plasmin, trypsin, chymotrypsin, 
kallikrein and activated protein C [41] and α-2-antiplasmin, which targets predominantly 
neutrophil elastase and plasmin [42], were used.  
 
There were significant reductions in invasive activity of 55% (Figure 6A; 95% CI, 
199.5 to 226.5, P<0.0001) and 70% (Figure 6B; 95% CI, 71.7 to 134.9, P<0.0001) when 
S100P expressing cells were treated with 25 μg/mL aprotinin or 10 μg/mL α-2-
antiplasmin, respectively. There was no significant reduction in the invasion of control 
S100P-negative cells by either aprotinin (Figure 6A; 95% CI, -5.5 to 21.5, P = 0.24) or 
α-2-antiplasmin (Figure 6B; 95% CI, -31.9 to 31.3, P = 0.98).  Whereas α-2-
antiplasmin did not significantly reduce the invasive potential of cells expressing the 
mutant S100P proteins (Figure 6B; K95A, 95% CI, -39.3 to 23.9, P = 0.62; ΔK95, 95% 
CI, -37.3 to 25.9, P = 0.72), aprotinin reduced the invasive potential of cells expressing 
the K95A mutant protein (Figure 6A; K95A, 95% CI, 16.9 to 43.8, P<0.0001), but not 
significantly for the ΔK95 mutant (95% CI, -17.5 to 9.5, P = 0.55). These results 
demonstrate that the stimulatory effect of S100P on invasion involves the 
plasmin/plasminogen pathways, as these specific protease inhibitors significantly 
disrupted cell invasion. 
 
 
Discussion 
 
It has been shown here for the first time that soluble rS100P protein can activate tPA in 
vitro. The 7.6-fold activation over that with tPA alone is comparable with that of ~9-
fold for S100A4 [18], but less than the 46-fold activation reported for S100A10 [43]. 
Deleting the C-terminal lysine of S100P (Δ95K, exposing a C-terminal leucine) or 
changing it to alanine (K95A), with no change in the dimeric state of the rS100P, 
reduced the rates of activation of tPA to only16% and 22%, respectively, of the non-
mutant S100P protein, similar to the 15% of activity remaining upon deletion of the two 
C-terminal lysines of S100A10 [43], reflecting the involvement of non-C-terminal 
lysine side chains [21].  
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Direct interaction in vitro between non-mutant S100P and Glu-plasminogen or tPA, 
individually, has been demonstrated, with Kd values (0.12 μM and 1.9 μM, 
respectively) similar to those for S100A10 binding to Glu-plasminogen (0.66 µM, 
calculated in the present experiments (not shown) and 1.81 µM reported previously 
[19]) and to tPA of 0.45 µM [19]. However, for S100P, there were differences between 
the interactions of S100P with Glu-plasminogen and tPA.  Whereas the interaction of 
S100P with tPA required the presence of calcium ions, S100P still bound to Glu-
plasminogen in the absence of calcium. In contrast, the C-terminal lysine mutants of 
S100P did not bind to Glu-plasminogen, but did bind to tPA, a result which contrasts 
with that obtained with S100A10 [19].  Thus, the observed dependence of rS100P-
mediated plasminogen activation on both the presence of calcium ions and the presence 
of the C-terminal lysine residue, is explained by the former requirement for binding of 
S100P to tPA and the latter requirement for binding to Glu-plasminogen.  
 
In the present multiwell experiments, significant activation of plasminogen activator 
was detectable with only 50 – 100 nM rS100P (< 1 μg/mL). S100P has been reported to 
be present in the extracellular environment [44, 45], but at presently unknown 
concentration. However, the observation that cells constitutively-expressing either of 
the mutants exhibited reduced plasminogen activation rates compared to those 
expressing non-mutant rS100P protein and in a separate cell system, inducible 
upregulation of S100P enhanced plasminogen activation, shows for the first time that 
cell-produced S100P can modulate plasminogen activation.  
 
The main findings in this paper are that for the first time, the activation of tPA by an 
S100 protein in a tumour setting is linked to cell invasion. Elevated levels of tPA have 
been associated with tumour-associated cell activities in pancreatic cancer cells, but 
these were not linked specifically to an increase in plasmin activity [46].   
 
In the present experiments, plasmin activity, and thus plasminogen activation, has been 
directly and specifically linked to S100P-directed cell invasion by the use of inhibitors 
of plasmin activity, aprotinin or α-2-antiplasmin. The specificity of α-2-antiplasmin for 
plasmin [42] has been used previously to show the involvement of plasmin and tPA in 
chemotactic migration of human T cells [47]. Aprotinin and α-2-antiplasmin, 
individually, significantly inhibited S100P-promoted invasion, but the inhibitors had no 
effect on invasion by S100P-negative cells, and α-2-antiplasmin had no inhibitory effect 
on cells expressing the K95A or ΔK95 mutant S100P proteins. These results show a 
direct involvement of plasmin activation in S100P-driven cell invasion. Enhancement of 
cell invasion by plasmin proteolytic activity is well established in normal tissue [48] and 
tumours [49, 50].    
 
Given the link between plasmin activation and cell invasion in S100P expressing cells, 
the activation of tPA, demonstrated in vitro and in cultured cells, might contribute to the 
previously-reported metastasis inducing properties of S100P [7]. Neither the S100P-
expressing cells, nor the control cells, exhibited detectable plasminogen mRNA by PCR 
(Supplementary information 7), however, the average blood concentration of 
plasminogen (1.33 μM; [51]) is much greater than both the Glu-plasminogen 
concentration used in the in vitro assays (100 nM) and the experimentally-determined 
Kd values for the S100P:Glu-plasminogen interaction (0.12 μM); thus, at suitable S100P 
concentrations in vivo, S100P:plasminogen interaction could take place during the 
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metastatic process. However, in contrast, the average blood concentration of tPA of 
only 0.143 nM [51] is much lower than both the concentration of tPA used in the in 
vitro multiwell assay, in order to detect suitably large optical density changes, and the 
measured Kd for the interaction between S100P and tPA (1.9 μM). However, the Rama 
37 cells do produce PCR-detectable tPA mRNA (Supplementary information 7), which, 
if translated into active tPA protein, could locally raise the tPA concentration in the 
surrounding medium.  
 
S100P has been detected on the cell surface from outside the cell using an antibody 
(Figure 5), which also reduced the cell invasion (Figure 6). Thus, on the cell surface, 
S100P might be complexed with other cell components.  S100A10, a major tPA 
activator, exhibits a 340-fold increase in tPA activation when it is associated with its 
natural cell surface receptor, annexin AII [52]. The cells used in the present experiments 
exhibit abundant levels of annexin AII mRNA and protein by PCR (not shown) and 
Western blot (Supplementary information 8), respectively. However, so far, it has not 
been possible to show, experimentally in vitro, a physical interaction between S100P 
and commercially available recombinant annexin AII protein under conditions in which 
S100A10 (Kd  = 3.7 ± 1.1 x 10-8 M) and S100A4 (Kd  = 3.45 ± 1.7 x 10-6 M) bind to 
immobilised annexin AII (Sourav, V. and Barraclough, R, unpublished observation).  In 
other systems, S100P interacts/colocalises in surface protrusions with the cytoskeletal 
protein ezrin [28, 53] and interacts with the adaptor protein, IQGAP1 [29]. Both these 
proteins localise to the cortical cytoskeleton in contact with the cell membrane [54]. 
Elsewhere, extracellular S100P, has been reported to interact with the RAGE receptor 
[45].  Based on the assumption that binding of S100P to these proteins would allow 
contact of the S100P C-terminal lysine with tPA, these various proteins might provide a 
means for displaying S100P on the outside of the cell and thereby enhance its ability to 
activate plasminogen activator. 
 
 
Figure legends 
 
Figure 1. S100P enhances the rate of plasminogen activation by tissue plasminogen 
activator in a cell-free multiwell assay  
(A), a multiwell colorimetric assay for the generation of plasmin from Glu-plasminogen 
was carried out as described in Materials and Methods in a buffer consisting of 50 mM 
Tris-HCl, pH 7.4, 100 mM NaCl and 5 mM CaCl2 either without (curve 1) or with t-PA 
and 0 (curve 2), 0.24 (curve 3), 0.48 (curve 4), 0.72 (curve 5), 2.4 (curve 6) or 3.4 
(curve 7) μM rS100P wild type. (B), as (A), but with a rS100P mutant protein, ΔK95, in 
which the C-terminal lysine had been deleted.  (C), as (A), but with a rS100P mutant 
protein, K95A, in which the C-terminal lysine had been replaced with alanine. The 
accumulation of plasmin from Glu-plasminogen was monitored colorimetrically at 405 
nm at 5-min intervals up to 120 min.  (D), initial gradients of plots of optical density vs 
time (min)2 for wild type ( ), deletion mutant, ΔΚ95 ( ) and substitution mutant, 
K95A ( ). 
 
Figure 2. S100P-dependent activation of plasminogen activator in a multiwell assay 
Plasminogen activation assays were carried out in the presence of excess tPA and the 
activation of plasminogen was monitored by the appearance of colour arising from the 
cleavage of a plasmin-specific substrate as described in Materials and Methods. The 
initial gradients of optical density against time (min)2 over the first 30 min are plotted 
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for each experimental treatment. Error bars are the means of two determinations carried 
out at the same time (A, B and C) or three independent experiments (D).  In (A), assays 
were carried out with 1 μM rS100P and the various concentrations of calcium chloride 
indicated; in (B), in the presence of 5 mM calcium chloride with no added protein or 
with 1 μM rS100P or with 1 μM bovine serum albumin. In (C), assays were carried out 
in the presence of 100 μM calcium chloride and varying concentrations of rS100P 
shown in the figure. P values (ANOVA with Bonferroni correction) are shown for each 
concentration relative to the zero rS100P control. In (D), assays were carried out with 
100 μM calcium chloride and 1 μM of wild type rS100P, K95A mutant, ΔK95 mutant 
or BSA. 
 
Figure 3. S100P binding to plasminogen, tPA and uPA  
(A and B), ligand surfaces, Glu-plasminogen (A) and tPA (B), were prepared via amine 
coupling reactions as described in Materials and Methods. Wild type (black lines) and 
mutant S100P proteins, K95A (red lines), ΔK95 (green lines) were injected over the 
prepared surfaces and binding interactions determined by changes in surface plasmon 
resonance. Both the running buffer and analyte dilution buffer contained 100 µM CaCl2. 
Wild type S100P protein was also tested with 0.5 mM EGTA (orange lines) and 10 mM 
6-ACA (violet lines), which were added to the analyte samples only. Duplicate analyses 
are shown, except for wild type S100P, which served as a positive control.  (C) Lack of 
effect of S100P on the activation of plasminogen by uPA in a multiwell assay.  
Plasminogen activation assays were carried out in the presence of increasing 
concentrations of uPA and the activation of plasminogen was monitored by the 
appearance of colour arising from the cleavage of a plasmin-specific substrate as 
described in Materials and Methods. The initial gradients of optical density against time 
(min)2 over the first 30 min are plotted for each experimental treatment in the absence 
(black bars) or presence (white bars) of 1 μM rS100P. Error bars are the means of 
duplicate determinations carried out at the same time. (D) uPA ligand surfaces were 
prepared via amine coupling reactions, as described in Materials and Methods. 
Plasminogen (blue line), wild type rS100P (black lines) and mutant rS100P proteins, 
K95A (red lines) or ΔK95 (green lines) were injected over the prepared surfaces and 
binding interactions determined as for the Glu-plasminogen and tPA surfaces. Both the 
running buffer and analyte dilution buffer contained 100 µM CaCl2. 
 
Figure 4. Activation of plasminogen by S100P  
(A-C) S100P positive and parental S100P-negative cell lines were cultured in normal 
medium and the medium changed to PBS.  Glu-plasminogen, tPA and chromogenic 
substrate were added as described in Materials and Methods and the cells incubated at 
37° C.  At 10-min intervals, samples of the medium were taken and the optical density 
of the coloured product of plasmin activity was measured. The initial gradients of colour 
development with time were normalised to the initial gradients for wild type S100P-
containing cells for each of 6 independent experiments (A) using cloned and pooled cell 
lines with wild type S100P (black columns), S100P ΔK95 mutant (white columns), 
S100P K95A mutant (grey columns), S100P-negative empty vector control cell 
lines/pools (dotted columns) and parental untransfected Rama 37 cells (striped 
columns). (B) shows the mean and standard deviations of the pooled results from (A). 
The key to the patterns of the bars is shown for panels A and B.  In (C), a similar 
experiment was carried out on Rama 37 cells bearing a doxycycline-inducible promoter, 
before and after induction of S100P.   
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Figure 5.  ELISA quantitation of S100P and eEF1A antibody binding to the 
surface of S100P-negative and S100P-positive living cells   
Antibodies to S100P (A) or eEF1A (B) were added to the medium surrounding cultured 
cells and incubated for 1 h (Antibody in medium), or the cells were fixed with 3.7 % 
(w/v) paraformaldehyde in PBS prior to adding antibody (Antibody after fixation), or 
the cells were subjected to permeabilisation with Triton X-100 and fixation with 3.7% 
(w/v) paraformaldehyde in PBS, prior to adding the antibody (Antibody after 
permeabilisation).  The cells were subject to an antibody-detecting ELISA and the 
optical density of the resulting colour determined, as described in Materials and 
Methods. White bars, S100P-negative cells, black bars, S100P-positive cells.  Error bars 
are ± SD of triplicate determinations in representative experiments.  P values are 
derived from one-way ANOVA with Bonferroni correction).  
 
 
Figure 6. The effect of extracellular addition of 6-aminocaproic acid, an S100P 
antibody, aprotinin or α-2-antiplasmin on the rate of invasion through Matrigel by 
cells expressing wild type and mutant S100P proteins. 
Cell invasion assays were carried out in transwell chambers coated with Matrigel, as 
described in Materials and Methods. The mean numbers of cells passing through the 
Matrigel are plotted for cells expressing wild type S100P (Rama 37 + S100P), K95A-
mutant of S100P (Rama 37 + S100P K95A), ΔK95 mutant of S100P (Rama 37 + 
S100P ΔK95), or cells not expressing S100P (Rama 37 + vector control). Results are 
expressed as a % of the invasion of the untreated Rama 37 + S100P cells. (A) The effect 
on cell invasion of 10 mM 6-aminocaproic acid (ACA; striped bars) or 25 μg/mL 
aprotinin (light grey bars) in the extracellular medium.  (B) The effect on cell invasion 
of a five-hundred-fold dilution of a goat S100P antibody (stippled bars) or 10 μM α-2-
antiplasmin (black bars) added to the extracellular medium. (C) The effect of non-
immune goat serum on cell invasion (black bars). White bars in all panels are untreated 
cells normalised to 100%. Error bars are ± SD of 3 replicates within a single 
experiment. P values (ANOVA with Bonferroni correction) are shown.  
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Supplementary information 1.  Expression of S100P in transfected Rama 37 cells 
 
Immunoblot of S100P protein levels in cloned cell lines and pooled cells of transfected Rama 37 
cells expressing S100P wild type or mutants.   Extracts of cells were separated by SDS 
polyacrylamide gel electrophoresis and blotted onto polyvinylidene difluoride (PVDF) 
membrane.  The blot was incubated either with anti-human S100P antibody (Panel A) or with 
anti-actin antibody (Panel B) as a loading control.  Bound antibodies were detected by 
chemiluminescence with HRP-conjugated secondary antibody. Clones and pools of cells 
transfected with expression vector containing cDNAs encoding S100P proteins contain similar 
levels of S100P protein, whereas the parental untransfected cells and cells transfected with  
empty expression vector contain levels of S100P protein undetectable by immunoblotting. 
 
 
 
 
Supplementary information 2. Purification of recombinant S100P 
 
Wild type S100P protein was expressed in BL21 (DE3) E. coli cells (as described in 
Materials and Methods) and samples were collected at each stage of purification: following 
cell lysis and centrifugation (Supernatant), passing of lysate through a HisTrap column 
(Flowthrough), elution of bound protein from the HisTrap column (HisTrap elution), removal 
of His-tag using a thrombin-agarose column (Thrombin column elution fractions) and final 
clean-up using a Superdex® 75 gel filtration column (Gel filtration fractions). The samples 
were subjected to SDS polyacrylamide gel electrophoresis and the gel stained with 
Coomassie Brilliant blue stain to visualise the proteins. 
 
 
 
Supplementary information 3.   Size Exclusion Chromatography-Multi-Angle Light 
Scattering of wild type and mutant S100P recombinant proteins 
 
Recombinant wild type S100P or mutant proteins were subjected to Size Exclusion 
Chromatography-Multi-Angle Light Scattering as described in Material and Methods.  At both 
500 and 50 M calcium, all three proteins contained 96%-97% dimeric form with only 3-4% of 
the protein in a higher, mainly tetrameric molecular mass form.  At 500 M calcium, the mean 
molecular masses of the dimeric form for wild type, 95K and K95A mutant proteins were 19.9 ± 
SD 0.3, 19.5 ± SD 0.15 and 19.5 ± SD 0.2 kDa, respectively, values that were similar to the 
molecular masses obtained at 50 M calcium of 20.0 ± SD 0.2, 19.2 ± SD 0.2 and 19.4 ± SD 0.1  
kDa. There was no evidence of monomeric S100P at either 50 or 500 M calcium ion 
concentration. 
 
 
 
Protein 
(Calculated 
monomeric  
mass Da) 
Conc’n  
of Ca
++
 
Dimeric mass (Da) 
(% total protein) 
 
Tetrameric  
mass (Da) 
(% total protein) 
 
Pentameric  
mass (Da) 
(% total protein) 
 
S100P Wild 
Type 
(10,400) 
50 M 
 
500 M 
19,597±181 (96.7%) 
 
19,930±266 (96.1%) 
41,800±936 (1.6%) 
 
41,849±2,291 (3.9%) 
50,481±1,286 (1.7%) 
 
- 
S100P Stop 
mutant 
(10,254) 
50 M 
 
500 M 
19,202±202 (96.2%) 
 
19,512±158 (96.5%) 
39,397±840 (3.8%) 
 
37,730±1,741 (3.5%) 
- 
 
- 
S100P A 
mutant 
(10,421) 
50 M 
 
500 M 
19,370±104 (96.3%) 
 
19,506±231 (97%) 
41,390±1,420 (3.7%) 
 
37,485±1,527 (3%) 
- 
 
- 
 
Supplementary information 4.  Binding of S100P to Glu-plasminogen and tPA 
 
Binding kinetics of wild-type recombinant (r)S100P with Glu-plasminogen and tPA surfaces. 
Both Glu-plasminogen (A) and tPA (B) surfaces were prepared using amide-coupling, as 
described in Materials and Methods. Wild-type rS100P was injected at the indicated protein 
concentrations over the surface in a buffer containing 100 µM CaCl2. Experiments were run 
in duplicate, and the mean response values for each protein concentration are shown. 
 
 
 
Supplementary information 5.  Assay for plasminogen activation in PBS buffer 
 
Multiwell tissue plasminogen activator (t-PA) activation assays were carried out as described in 
Materials and Methods in phosphate-buffered saline.  The rate of accumulation of coloured 
plasmin product was monitored over a 2-hour period for incubations containing 0-7 g 
recombinant human S100P. Plots of optical density against time squared gave straight-line 
graphs, which were used to compare the plasminogen activator stimulating activity of S100P 
proteins. A, B, Wild type S100P; C, D, 95K S100P; E, F, K95A S100P (ug = g). 
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Supplementary information 6.  Invasion through Matrigel of cell clones and pools. 
 
Transwell invasion assays were carried out as described in Materials and Methods using 
25,000 cells in the upper chambers and a 1-5% gradient of foetal calf serum between the 
upper and lower chambers.  Control cells comprised parental untransfected Rama 37 cells 
(Rama 37) and cells transfected with empty vector (Rama 37 + vector).  Results are shown 
for a clone and pool of cells resulting from transfection with expression vector containing 
cDNA for: wild type S100P (Rama 37 + S100P wild type), 95K (Rama 37 + S100P 95K) 
and K95A mutants (Rama 37 + S100P K95A).  A final control of Rama 37 cells transfected 
with wild type S100P, but with 5% foetal calf serum in upper and lower chambers, was 
included (Rama 37 + S100P wild type equal serum).  The cloned cell lines were used in the 
experiments described in the main body of the paper. 
 
 
 
Supplementary information 7.  The levels of plasminogen and tPA mRNAs in Rama 37 
cells by polymerase chain reaction (PCR). 
 
Plasminogen mRNA. PCR reactions were carried out in the absence or presence of cDNA 
isolated from control, S100P-negative, Rama 37 cells transfected with empty expression vector, 
or Rama 37 cells transfected with expression vector containing S100P cDNA and expressing 
S100P protein (Supplementary information 1) or with rat liver cDNA as a positive control. The 
plasminogen mRNA-specific primers were forward 5’-AAACACCTCATAGGCACAAC-3’ and 
reverse 5’-CTTCAGGTTGCAGTATTCCC-3’ and the PCR reactions consisted of 35 cycles of  
30 s at  95°C, 30 s at  50°C and 90 s at 72°C.  The PCR mixture was subjected to agarose gel 
electrophoresis along with a 100 bp ladder.  No bands of amplification were detected in the 
cDNA from Rama 37-derived cells, either in the absence or presence of cDNA.  However, in the 
same experiment under the same conditions, an amplified band of the expected size of 452 bp 
was obtained from rat liver cDNA. 
 
 
 
 
tPA mRNA. PCR reactions were carried out in the absence or presence of cDNA isolated from 
control S100P-negative, Rama 37 cells transfected with empty expression vector or Rama 37 
cells transfected with expression vector containing S100P cDNA and expressing S100P protein 
(Supplementary information 1) or with rat kidney cDNA as a positive control. The tPA mRNA-
specific primers were forward 5’-TGGCACCCACAGCTTTACCACATCCAAGG-3’ and 
reverse 5’-CTCCTGAGTCACCTGGCACGCGTCATGG-3’ and the PCR reactions consisted of 
35 cycles of  30 s at  95°C, 30 s at  56°C and 90 sec at  72°C.  The PCR mixture was subjected to 
agarose gel electrophoresis using a 100 bp ladder.  Bands of amplification of the expected size of 
908 bp were detected in the cDNA from Rama 37 cells and rat kidney, but there were no bands 
in the absence of cDNA.   
 
 
 
Supplementary information 8.  Annexin AII in Rama 37 cells 
Extracts of cell lines and pools expressing S100P and control S100P negative cells were cultured 
and extracts prepared for SDS polyacrylamide gel electrophoresis, as described in Materials and 
methods.  The extracts were subjected to gel electrophoresis and Western blotting with 
antibodies directed against annexin AII (BD Biosciences) or non-muscle actin (Sigma).  Bands 
corresponding to annexin AII (36 kDa) and actin (43 kDa) are shown for a pool of cells 
expressing the K95 S100P mutant (Rama 37 + S100P K95 pool); control S100P-negative 
Rama 37 empty vector transfected cell clone (Rama 37 + vector control clone); a pool (Rama 37 
+ S100P pool) and a clone (Rama 37 + S100P clone) of cells expressing wild type S100P; a 
clone of Rama 37 cells expressing the K95A mutant of S100P (Rama 37 + S100P K95A clone).  
All cells expressed annexin AII protein. 
 
 
